Affiliation:
1. Emergency Department Royal Melbourne Hospital Melbourne Victoria Australia
2. Department of Critical Care University of Melbourne Melbourne Victoria Australia
3. Pathology and Clinical Governance Australian Red Cross Lifeblood West Melbourne Victoria Australia
4. Transfusion Research Unit School of Public Health and Preventive Medicine Monash University Prahran Victoria Australia
Abstract
AbstractBackgroundNucleic acid test window periods for HIV, HCV, and HBV facilitate estimation of the residual risk of unexpected disease transmission and assist clinicians in determining the timeframe in which a recently acquired infection is at risk of nondetection.ObjectivesFirstly, to provide revised estimates of the NAT window periods based on a currently used triplex NAT assay. Secondly, to examine their validity in organ donation and transplantation practice.MethodEstimates were based on the Procleix Ultrio Elite Assay (Grifols Diagnostic Solutions Inc. California, USA). The manufacturer's X50 and X95 limits of detection (LOD) were utilised. Viral doubling times of 0.85, 0.45, and 2.56 days and conversion factors for IU per ml to copies per mL of 0.6, 3.4, and 5 were assumed for HIV, HCV, and HBV respectively. Window periods were derived from the X50 and X95 LODs, based on a range of potential inoculum volumes.ResultsCalculated X50 window periods were 5.1 (4.5–5.8), 2.7 (2.4–2.9), and 16.6 (14.2–19.1) days for HIV, HCV, and HBV respectively.Calculated X50 window periods, based on
whole body plasma volume, were 11.8 (10.3–13.3), 6.2
(5.6–6.8) and 36.7 (31.3–42.1) days respectively.ConclusionX50 NAT window periods were significantly shorter for HBV and HCV and sit at the lower range of previously published estimates for HIV . Current modeling assumptions may not account for all unexpected transmission events and may no longer be suitable for application to organ donation and transplantation.
image
Subject
Infectious Diseases,Transplantation
Reference43 articles.
1. Clinical guidelines for organ transplantation from deceased donors. Transplant Society of Australia and New Zealand. Accessed April 16 2023.https://tsanz.com.au/storage/documents/TSANZ_Clinical_Guidelines_Version‐110_Final.pdf
2. Donor-derived hepatitis C in the era of increasing intravenous drug use: A report of the Disease Transmission Advisory Committee
3. International application of the Incidence Rate/Window Period model
4. Residual risk of infection with blood‐borne viruses in potential organ donors at increased risk of infection: systematic review and meta‐analysis
5. Vigilance and Surveillance Advisory Committee. Australian Vigilance and Surveillance System for Organ Donation and Transplantation: Quarterly Communique– 01 October 2020 to 31 December 2020 1–2. Australian Organ and Transplantation Authority.(2020).